Cargando…

Deoxythymidine kinase in the tumour cells and serum of patients with non-Hodgkin lymphomas.

The levels of deoxythymidine kinase in tumour cells (C-TK) and in serum (S-TK) were investigated and the tumour volume calculated in 89 patients with non-Hodgkin lymphoma (NHL), in order to ascertain the importance of C-TK and tumour burden as regards the S-TK levels. Among all patients, a correlati...

Descripción completa

Detalles Bibliográficos
Autores principales: Rehn, S., Gronowitz, J. S., Källander, C., Sundström, C., Glimelius, B.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1995
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033808/
https://www.ncbi.nlm.nih.gov/pubmed/7734308
_version_ 1782136918273687552
author Rehn, S.
Gronowitz, J. S.
Källander, C.
Sundström, C.
Glimelius, B.
author_facet Rehn, S.
Gronowitz, J. S.
Källander, C.
Sundström, C.
Glimelius, B.
author_sort Rehn, S.
collection PubMed
description The levels of deoxythymidine kinase in tumour cells (C-TK) and in serum (S-TK) were investigated and the tumour volume calculated in 89 patients with non-Hodgkin lymphoma (NHL), in order to ascertain the importance of C-TK and tumour burden as regards the S-TK levels. Among all patients, a correlation was seen between S-TK and tumour volume but not between S-TK and C-TK. However, within different tumour volume categories (small, medium-sized and large), there was a correlation between S-TK and C-TK. Multiple regression analysis supported this notion. C-TK correlated with the proliferation-associated parameters, S-phase fraction and mitotic index. As already known, S-TK was found to have a strong prognostic value. C-TK and tumour burden were also of prognostic value. In multivariate analyses, C-TK and tumour volume did not provide prognostic information in addition to S-TK, whereas, in the absence of S-TK, C-TK and tumour volume did provide additional information. It is concluded that the serum level of TK depends on both the tumour burden and the tumour cell proliferation rate. Based upon estimations of S-TK in patients assessed shortly after chemotherapy, we also suggest that S-TK reflects the number of proliferating cells that have died during the period immediately before sampling.
format Text
id pubmed-2033808
institution National Center for Biotechnology Information
language English
publishDate 1995
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20338082009-09-10 Deoxythymidine kinase in the tumour cells and serum of patients with non-Hodgkin lymphomas. Rehn, S. Gronowitz, J. S. Källander, C. Sundström, C. Glimelius, B. Br J Cancer Research Article The levels of deoxythymidine kinase in tumour cells (C-TK) and in serum (S-TK) were investigated and the tumour volume calculated in 89 patients with non-Hodgkin lymphoma (NHL), in order to ascertain the importance of C-TK and tumour burden as regards the S-TK levels. Among all patients, a correlation was seen between S-TK and tumour volume but not between S-TK and C-TK. However, within different tumour volume categories (small, medium-sized and large), there was a correlation between S-TK and C-TK. Multiple regression analysis supported this notion. C-TK correlated with the proliferation-associated parameters, S-phase fraction and mitotic index. As already known, S-TK was found to have a strong prognostic value. C-TK and tumour burden were also of prognostic value. In multivariate analyses, C-TK and tumour volume did not provide prognostic information in addition to S-TK, whereas, in the absence of S-TK, C-TK and tumour volume did provide additional information. It is concluded that the serum level of TK depends on both the tumour burden and the tumour cell proliferation rate. Based upon estimations of S-TK in patients assessed shortly after chemotherapy, we also suggest that S-TK reflects the number of proliferating cells that have died during the period immediately before sampling. Nature Publishing Group 1995-05 /pmc/articles/PMC2033808/ /pubmed/7734308 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Rehn, S.
Gronowitz, J. S.
Källander, C.
Sundström, C.
Glimelius, B.
Deoxythymidine kinase in the tumour cells and serum of patients with non-Hodgkin lymphomas.
title Deoxythymidine kinase in the tumour cells and serum of patients with non-Hodgkin lymphomas.
title_full Deoxythymidine kinase in the tumour cells and serum of patients with non-Hodgkin lymphomas.
title_fullStr Deoxythymidine kinase in the tumour cells and serum of patients with non-Hodgkin lymphomas.
title_full_unstemmed Deoxythymidine kinase in the tumour cells and serum of patients with non-Hodgkin lymphomas.
title_short Deoxythymidine kinase in the tumour cells and serum of patients with non-Hodgkin lymphomas.
title_sort deoxythymidine kinase in the tumour cells and serum of patients with non-hodgkin lymphomas.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033808/
https://www.ncbi.nlm.nih.gov/pubmed/7734308
work_keys_str_mv AT rehns deoxythymidinekinaseinthetumourcellsandserumofpatientswithnonhodgkinlymphomas
AT gronowitzjs deoxythymidinekinaseinthetumourcellsandserumofpatientswithnonhodgkinlymphomas
AT kallanderc deoxythymidinekinaseinthetumourcellsandserumofpatientswithnonhodgkinlymphomas
AT sundstromc deoxythymidinekinaseinthetumourcellsandserumofpatientswithnonhodgkinlymphomas
AT glimeliusb deoxythymidinekinaseinthetumourcellsandserumofpatientswithnonhodgkinlymphomas